Canaccord Genuity Maintains a 'Hold' on United Therapeutics (UTHR); Increasing FY12 Adcirca and Tyvaso Revenues
Tweet Send to a Friend
Canaccord Genuity maintains a 'Hold' on United Therapeutics Corp. (NASDAQ: UTHR) price target of $44.00.
Analyst, Salveen Richter, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Salveen Richter, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
